![](/wp-content/uploads/2018/10/yrTWi38UStCQvrCjiAbc.png)
$599
Dexcom Q3 ’21 Earnings Update
Dexcom hosted its Q3 ’21 earnings call (press release; slides) and provided updates to its clinical and commercial activities, including the G7 OUS launch anticipated later in 2021 as well as the impending G7 510(k) submission “in the next few weeks.” Below, FENIX provides highlights and insights from the call.